comparative study of natural micronized progestrone and gonadotropin-releasing hormone agonist in the control of bleeding during hysterescopic myomectomy in women with abnormal uterine bleeding

The main objective of this study is comparative study of natural micronized progestrone and gonadotropin-releasing hormone agonist in the control of bleeding during hysterescopic myomectomy in women with abnormal uterine bleeding . The study included 50 patients with complaints abnormal uterine bleeding that refer to Alzahra hospital for hysteroscopic myomectomy will be done. Patients randomly using random software list will be divided into two groups of 25 people. Patients with abnormal uterine bleeding and submucosal myoma with a diameter of 30 mm or less and zero or first grade will be incloud to this study. of All patients in both groups of informed consent will be obtained. Both groups were matched for age, gravid, parity and the number of myoma And patients with a history of underlying disease, submucosal larger than 3 cm will be excluded. Random selection will be done by a nurse, that aware of the details of an investigation. Doctors and patients to selected groups will be blind. After random selection of patients by the respective resident, the first group of 100 mg of natural micronized progesterone capsules called Utrogestan will be used , from the first day of the period for 30 days, two capsules totaling 200 mg when sleeping 3 hours from the last meal with a glass of water will be used. In the second group 2 months before hysteroscopy, the injection of muscle will be 3.75 mg of dipyriline ampoule as a GnRH agonist compound on day 21 of the period to two doses of 28 days. The first group will be admitted to the surgery on the last day of Utrogestan and the second group will be 4 weeks after the second injection of GnRH. In this study, the changes of hemoglobin as the primary outcome and duration of surgery and the success rate in Myomectomy, is considered secondary outcome.

The study included 50 patients with complaints abnormal uterine bleeding that refer to Alzahra hospital for hysteroscopic myomectomy will be done.Then, patients were randomly divided into two control 1 and control 2.

The main objective of this study is comparative study of natural micronized progestrone and gonadotropin-releasing hormone agonist in the control of bleeding during hysterescopic myomectomy in women with abnormal uterine bleeding . The study included 50 patients with complaints abnormal uterine bleeding that refer to Alzahra hospital for hysteroscopic myomectomy will be done. Patients randomly using random software list will be divided into two groups of 25 people. Patients with abnormal uterine bleeding and submucosal myoma with a diameter of 30 mm or less and zero or first grade will be incloud to this study. of All patients in both groups of informed consent will be obtained. Both groups were matched for age, gravid, parity and the number of myoma And patients with a history of underlying disease, submucosal larger than 3 cm will be excluded. Random selection will be done by a nurse, that aware of the details of an investigation. Doctors and patients to selected groups will be blind. After random selection of patients by the respective resident, the first group of 100 mg of natural micronized progesterone capsules called Utrogestan will be used , from the first day of the period for 30 days, two capsules totaling 200 mg when sleeping 3 hours from the last meal with a glass of water will be used. In the second group 2 months before hysteroscopy, the injection of muscle will be 3.75 mg of dipyriline ampoule as a GnRH agonist compound on day 21 of the period to two doses of 28 days. The first group will be admitted to the surgery on the last day of Utrogestan and the second group will be 4 weeks after the second injection of GnRH. In this study, the changes of hemoglobin as the primary outcome and duration of surgery and the success rate in Myomectomy, is considered secondary outcome.

Patients with abnormal uterine bleeding and submucosal myoma with a diameter of 30 mm or less and zero or first grade will be incloud to this study

En Intervention group 1 : A 100 mg capsule of natural micronized progesterone called Utrogestan will be used, starting from the first day of the period for 30 days, two capsules of 200 mg will be used at bedtime with 3 hours from the last meal with a glass of water. En Intervention group 2: Intramuscular injection of 3.75 mg of diafililic ampoule as a GnRH agonist compound will be used on day 21 of the period two dose intervals of 28 days for 2 months prior to the hysteroscopy. .

En The hemoglobin concentration

Patients will randomly be divided into two groups using the Randlist version 1, 2, Dattng CmbH, Tubingen Germany software.

Random selection will be done by a nurse, that aware of the details of an investigation. Doctors and patients to selected groups will be blind.